Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of citronellic acid as vaccine production synergist

A technology of citronellic acid and a synergist is applied in the application field of citronellic acid as a synergist for virus or virus vaccine production, and achieves the effects of promoting SVA replication, efficient production and increased replication level

Active Publication Date: 2021-08-20
LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above studies mainly focus on the interaction regulation between SVA and key molecules in the innate immune pathway, but there are no reports on the promotion of SVA replication by chemical substances

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of citronellic acid as vaccine production synergist
  • Application of citronellic acid as vaccine production synergist
  • Application of citronellic acid as vaccine production synergist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1 Citronellic acid promotes the effect evaluation experiment of SVA replication

[0029] 1. Preparation of Medium Containing Citronellic Acid

[0030] In DMEM medium, different doses of citronellic acid were added to make the concentrations 0mg / L, 10mg / L and 20mg / L respectively.

[0031] 2. Sample Preparation of Citronellic Acid-Incubated Cells

[0032] The IB cells were incubated with the prepared medium containing citronellic acid, then inoculated with SVA / FJ-201 (1 MOI), and the supernatant was collected 8 hours after inoculation.

[0033] 3. Determination of SVA virus titer

[0034] Determine the TCID of the supernatant obtained in the previous step 50 , for virus titer analysis.

[0035] TCID 50 The assay steps are as follows: inoculate the IB cells into a 96-well plate 16 hours in advance, wash the IB cells with PBS 3 times after the cells form a monolayer, and inoculate the supernatant collected in step 2 (10 -1 -10 -10 ) were used as infection ...

Embodiment 2

[0037] Embodiment 2 Citronellic acid promotes the effect evaluation experiment of SVA replication

[0038] 1. Preparation of Medium Containing Citronellic Acid

[0039] In DMEM medium, different doses of citronellic acid were added to make the concentrations 0mg / L, 10mg / L and 20mg / L respectively.

[0040] 2. Sample Preparation of Citronellic Acid-Incubated Cells

[0041] The PK-15 cells were incubated with the prepared medium containing citronellic acid, then inoculated with SVA / FJ-201 (1 MOI), and the supernatant was collected 12 hours after inoculation.

[0042] 3. Determination of SVA virus titer

[0043] After infection with SVA, the cell supernatant was collected and measured by TCID50 for virus titer analysis. Determination of virus titer: IB cells were inoculated into a 96-well plate 16 hours in advance. After the cells formed a monolayer, the IB cells were washed 3 times with PBS, and the supernatant collected in step 2 (10 -1 -10 -10 ), and set up two columns of ...

Embodiment 3

[0045] The citronellic acid of embodiment 3 different concentrations promotes the duplication of SVA in PK-15 or IB cell

[0046] 1. Preparation of Medium Containing Citronellic Acid

[0047] In the DMEM medium, different doses of citronellic acid were added to make the concentrations respectively 0mg / L, 2.5mg / L, 5mg / L, 10mg / L, 20mg / L, 40mg / L and 50mg / L.

[0048] 2. Sample Preparation of Citronellic Acid-Incubated Cells

[0049] Incubate PK-15 cells with the prepared medium containing the above-mentioned different concentrations of citronellic acid, then inoculate SVA (1MOI), and collect the supernatant 12 hours after inoculation;

[0050] At the same time, the IB cells were incubated with the prepared medium containing the above-mentioned different concentrations of citronellic acid, then inoculated with SVA (1 MOI), and the supernatant was collected 8 hours after inoculation.

[0051] 3. Determination of SVA virus titer

[0052]Cell supernatants were collected after infec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biology, and particularly relates to application of citronellic acid as a virus or viral vaccine production synergist. The invention accidentally discovers that the replication level of SVA (Senecavirus A) can be remarkably increased by adding the citronellic acid into the culture medium for culturing the SVA, which indicates that the citronellic acid has the effect of promoting the replication of the SVA, can be used as a synergist for SVA virus expression or vaccine production, and can be used for efficient production of an SVA virus or virus vaccine.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to the application of citronellic acid as a synergist for the production of viruses or virus vaccines. Background technique [0002] Senecavirus (Senecavirus A, SVA) is the only member of the newly added Senecavirus genus in the family Picornaviridae. Its clinical symptoms are indistinguishable from those of foot-and-mouth disease. ulcer. As SVA is an emerging infectious disease, there is no commercial vaccine yet, and its pathogenic and immune mechanisms are still not fully understood. [0003] Previous studies have shown that RIG-I is a key molecule for SVA to activate innate immunity, but 2C and 3C of SVA pro The protein can reduce the protein expression of RIG-I, and has the opposite antagonistic function to RIG-I; 2C and 3C of SVA pro It can also activate Caspase-3 and induce apoptosis; 3C of SVA pro Use its own enzyme activity to cleave key natural immune molecules...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N7/00A61K39/125A61P31/14
CPCC12N7/00A61K39/12A61P31/14C12N2770/32051C12N2770/32034A61K2039/552
Inventor 郑海学刘会胜薛巧朱紫祥宋影影薛钊宁
Owner LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com